Q2 EPS Forecast for Axsome Therapeutics Boosted by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Monday, May 26th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of ($1.20) for the quarter, up from their prior estimate of ($1.27). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($3.97) EPS, Q1 2026 earnings at ($0.59) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at ($0.78) EPS, Q1 2027 earnings at $0.43 EPS and FY2027 earnings at $4.54 EPS.

Several other brokerages have also issued reports on AXSM. Needham & Company LLC reiterated a "buy" rating and set a $153.00 price target on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Mizuho upped their price target on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a report on Thursday, March 27th. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Axsome Therapeutics in a research note on Thursday, May 22nd. Truist Financial upped their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Wells Fargo & Company reiterated an "overweight" rating and issued a $165.00 price target (up from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $172.14.

Axsome Therapeutics Stock Up 2.3%

Shares of Axsome Therapeutics stock traded up $2.40 during trading on Thursday, hitting $107.56. 279,545 shares of the stock traded hands, compared to its average volume of 685,680. The stock has a market cap of $5.30 billion, a P/E ratio of -17.96 and a beta of 0.46. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13. The company has a fifty day moving average price of $106.72 and a two-hundred day moving average price of $106.21.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 20,000 shares of the firm's stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $103.45, for a total transaction of $2,069,000.00. Following the transaction, the chief operating officer now owns 5,783 shares in the company, valued at approximately $598,251.35. This trade represents a 77.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Coleman sold 3,750 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total value of $395,512.50. Following the transaction, the director now owns 50,387 shares in the company, valued at approximately $5,314,316.89. This trade represents a 6.93% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,423 shares of company stock worth $4,950,619. Insiders own 22.30% of the company's stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXSM. Caitong International Asset Management Co. Ltd bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $25,000. Quantbot Technologies LP bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $31,000. NBC Securities Inc. bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $31,000. AlphaQuest LLC bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $38,000. Finally, Neo Ivy Capital Management bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $41,000. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.